The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
Just a few months after inking a tie-up with Amgen, Bind Therapeutics has come back from the deal table with another marquee partner looking to use its nanoengineering platform to launch newly amped-up treatments into the clinic.
Bind Biosciences has landed an $8.7 million chunk of a planned $20 million raise designed to fuel the biotech's midstage study of its lead cancer drug.
For the first time BIND Biosciences has found a large drugmaker to commit major money to collaborate on a drug with its nanomedicine platform.
Anatoly Chubais is one of the most influential figures in the Russian government. And he's now using his influence to invest billions of dollars in new technology through Rusnano, a move that has benefited a slate of U.S. biotechs.
Bind Biosciences has scored some initial blows against cancers in humans, providing data that back up some of the promise of its nanomedicine Bind-014 in preclinical tests.
Serial biotech entrepreneurs Robert Langer and Omid Farokhzad are joining up with MIT's Dr. Stephen Lippard to launch a new drug developer--Blend Therapeutics--which will concentrate on the
A pair of Boston-area biotechs focused on some cutting-edge bionanotechnology inspired by MIT's prolific Bob Langer is splitting a $94.5 million investment windfall spearheaded by RusNano, a
MIT's Technology Review has unveiled its list of the top 50 innovators, and nine life science companies have made the list. Roche and Novartis are representing Big Pharma this year. Roche's work
In the beginning of the year, when Cambridge, MA-based Bind Biosciences took the wraps off an $11 million round , the biotech company aroused considerable interest in the venture community. That